---
title: "Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286542293.md"
description: "Bank of America Securities has reaffirmed a Buy rating on Inhibikase Therapeutics (IKT) with a price target of $6.00, while the stock closed at $1.86. Analyst Jason Zemansky, a 5-star analyst, reports a Strong Buy consensus with an average price target of $6.20, indicating a 233.33% upside. LifeSci Capital also maintains a Buy rating with a $5.00 target."
datetime: "2026-05-15T09:50:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286542293.md)
  - [en](https://longbridge.com/en/news/286542293.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286542293.md)
generator: "portal-rs"
---

# Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT)

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Buy rating on Inhibikase Therapeutics, with a price target of $6.00. The company’s shares closed yesterday at $1.86.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Zemansky is a 5-star analyst with an average return of 19.9% and a 56.33% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Biogen, Insmed, and Ligand Pharma.

Currently, the analyst consensus on Inhibikase Therapeutics is a Strong Buy with an average price target of $6.20, a 233.33% upside from current levels. In a report released on May 13, LifeSci Capital also maintained a Buy rating on the stock with a $5.00 price target.

### Related Stocks

- [IKT.US](https://longbridge.com/en/quote/IKT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth](https://longbridge.com/en/news/295752640.md)
- [Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts](https://longbridge.com/en/news/281741463.md)
- [Inhibikase raises $50M to fund PAH program](https://longbridge.com/en/news/292740299.md)
- [Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages](https://longbridge.com/en/news/284878661.md)
- [Roth MKM Reaffirms Their Buy Rating on Equillium (EQ)](https://longbridge.com/en/news/283066157.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**